Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Rogaratinib in Sarcoma With FGFR Alterations and SDH-Deficient GIST
NCT04595747Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rogaratinib in sarcoma, gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Started May 2021; status: active, not recruiting.
02
Drugs
rogaratinib
03
Conditions
sarcomagastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04595747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595747.